Skip to main content
Publications
Morris MJ, de Bono J, Nagarajah J, Sartor O, Wei XX, Nordquist LT, Koshkin VS, Chi KN, Krause BJ, Herrmann K, Rahbar K, Vickers A, Mirante O, Ghouse R, Fizazi K, Tagawa ST. Correlation analyses of radiographic progression-free survival with clinical and health-related quality of life outcomes in metastatic castration-resistant prostate cancer: analysis of the phase 3 VISION trial. Cancer. 2024 Oct 15;130(20):3426-35. doi: 10.1002/cncr.35438
Vinceti M, Filippini T, Violi F, Rothman KJ, Costanzini S, Malagoli C, Wise LA, Odone A, Signorelli C, Iacuzio L, Arcolin E, Mandrioli J, Fini N, Patti F, Lo Fermo S, Pietrini V, Teggi S, Ghermandi G, Scillieri R, Ledda C, Mauceri C, Sciacca S, Fiore M, Ferrante M. Pesticide exposure assessed through agricultural crop proximity and risk of amyotrophic lateral sclerosis. Environ Health. 2017 Aug 29;16(1):91. doi: 10.1186/s12940-017-0297-2
Hunter JE, Zepp JM, Gilmore MJ, Davis JV, Esterberg EJ, Muessig KR, Peterson SK, Syngal S, Acheson LS, Wiesner GL, Reiss JA, Goddard KA. Universal tumor screening for Lynch syndrome: assessment of the perspectives of patients with colorectal cancer regarding benefits and barriers. Cancer. 2015 Sep 15;121(18):3281-9. doi: 10.1002/cncr.29470
Casas L, Tischer C, Wouters IM, Torrent M, Gehring U, Garcia-Esteban R, Thiering E, Postma DS, de Jongste J, Smit HA, Borras-Santos A, Zock JP, Hyvarinen A, Heinrich J, Sunyer J. Early life microbial exposure and fractional exhaled nitric oxide in school-age children: a prospective birth cohort study. Environ Health. 2013 Dec 2;12:103. doi: 10.1186/1476-069X-12-103
Burris HA, Lebrun F, Rugo HS, Beck T, Piccart M, Neven P, Baselga J, Petrakova K, Hortobagyi GN, Komorowski A, Chouinard E, Young R, Gnant M, Pritchard KI, Bennett L, Ricci J-F, Bauly H, Taran T, Sahmoud T, Noguchi S. Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. Cancer. 2013 Mar 15;119(10):1908-15.
Maurel J, Martins AS, Poveda A, Lopez-Guerrero JA, Cubedo R, Casado A, Martinez-Trufero J, Ramon Ayuso J, Lopez-Pousa A, Garcia-Albeniz X, Garcia del Muro X, de Alava E. Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: a phase I-II study by the Spanish Group for Research on Sarcomas. Cancer. 2010 Aug 1;116(15):3692-701. doi: 10.1002/cncr.25111